CA3179048A1 - Use of bupropion and dextromethorphan combinations for treating neurological disorders - Google Patents
Use of bupropion and dextromethorphan combinations for treating neurological disordersInfo
- Publication number
- CA3179048A1 CA3179048A1 CA3179048A CA3179048A CA3179048A1 CA 3179048 A1 CA3179048 A1 CA 3179048A1 CA 3179048 A CA3179048 A CA 3179048A CA 3179048 A CA3179048 A CA 3179048A CA 3179048 A1 CA3179048 A1 CA 3179048A1
- Authority
- CA
- Canada
- Prior art keywords
- nnl
- dextronnethorphan
- bupropion
- human
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063002132P | 2020-03-30 | 2020-03-30 | |
| US63/002,132 | 2020-03-30 | ||
| US202063016178P | 2020-04-27 | 2020-04-27 | |
| US63/016,178 | 2020-04-27 | ||
| US202063032517P | 2020-05-29 | 2020-05-29 | |
| US63/032,517 | 2020-05-29 | ||
| US202063032567P | 2020-05-30 | 2020-05-30 | |
| US63/032,567 | 2020-05-30 | ||
| US16/894,713 US10898453B2 (en) | 2013-11-05 | 2020-06-05 | Bupropion as a modulator of drug activity |
| US16/894,713 | 2020-06-05 | ||
| PCT/US2021/024718 WO2021202419A1 (en) | 2020-03-30 | 2021-03-29 | Use of bupropion and dextromethorphan combinations for treating neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3179048A1 true CA3179048A1 (en) | 2021-10-07 |
Family
ID=77930161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3179048A Pending CA3179048A1 (en) | 2020-03-30 | 2021-03-29 | Use of bupropion and dextromethorphan combinations for treating neurological disorders |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4125837A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7637150B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220161414A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115697314A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3179048A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021202419A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12194006B2 (en) | 2013-11-05 | 2025-01-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12109178B2 (en) | 2013-11-05 | 2024-10-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12569479B2 (en) | 2016-05-25 | 2026-03-10 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12472156B2 (en) | 2020-06-05 | 2025-11-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US20250073188A1 (en) | 2020-06-05 | 2025-03-06 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12433884B2 (en) | 2020-06-05 | 2025-10-07 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| CN122440635A (zh) | 2020-12-01 | 2026-07-24 | 安泰赛普生物风投二代有限责任公司 | 用于降低抑郁症患者的自杀风险的安非他酮和右美沙芬 |
| CA3227072A1 (en) * | 2021-07-21 | 2023-01-26 | Antecip Bioventures Ii Llc | Treatment of depression |
| JP2025517368A (ja) * | 2022-05-17 | 2025-06-05 | アンテシップ バイオベンチャーズ トゥー エルエルシー | うつ病の治療 |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US12156914B2 (en) | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| US12194036B2 (en) | 2022-07-07 | 2025-01-14 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11844797B1 (en) | 2023-04-20 | 2023-12-19 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| KR20250114110A (ko) * | 2022-11-28 | 2025-07-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 약물 활성의 조절제로서의 부프로피온 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3981403A1 (en) * | 2013-11-05 | 2022-04-13 | Antecip Bioventures II LLC | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
| US11234946B2 (en) * | 2013-11-05 | 2022-02-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9763932B2 (en) * | 2013-11-05 | 2017-09-19 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US10898453B2 (en) * | 2013-11-05 | 2021-01-26 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11007189B2 (en) * | 2013-11-05 | 2021-05-18 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US11273134B2 (en) * | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
-
2021
- 2021-03-29 CN CN202180038675.3A patent/CN115697314A/zh active Pending
- 2021-03-29 EP EP21779322.3A patent/EP4125837A4/en active Pending
- 2021-03-29 KR KR1020227037493A patent/KR20220161414A/ko active Pending
- 2021-03-29 JP JP2022559518A patent/JP7637150B2/ja active Active
- 2021-03-29 CA CA3179048A patent/CA3179048A1/en active Pending
- 2021-03-29 WO PCT/US2021/024718 patent/WO2021202419A1/en not_active Ceased
-
2024
- 2024-12-06 JP JP2024212992A patent/JP7890382B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023519965A (ja) | 2023-05-15 |
| KR20220161414A (ko) | 2022-12-06 |
| EP4125837A4 (en) | 2024-03-20 |
| WO2021202419A1 (en) | 2021-10-07 |
| JP7637150B2 (ja) | 2025-02-27 |
| CN115697314A (zh) | 2023-02-03 |
| JP2025032232A (ja) | 2025-03-11 |
| EP4125837A1 (en) | 2023-02-08 |
| JP7890382B2 (ja) | 2026-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11524008B2 (en) | Bupropion as a modulator of drug activity | |
| US11571417B2 (en) | Bupropion as a modulator of drug activity | |
| US11541048B2 (en) | Bupropion as a modulator of drug activity | |
| US11969421B2 (en) | Bupropion as a modulator of drug activity | |
| US11524007B2 (en) | Bupropion as a modulator of drug activity | |
| US11571399B2 (en) | Bupropion as a modulator of drug activity | |
| US11617728B2 (en) | Bupropion as a modulator of drug activity | |
| US11382874B2 (en) | Bupropion as a modulator of drug activity | |
| US11510918B2 (en) | Bupropion as a modulator of drug activity | |
| US11617747B2 (en) | Bupropion as a modulator of drug activity | |
| US11590124B2 (en) | Bupropion as a modulator of drug activity | |
| US11147808B2 (en) | Method of decreasing the fluctuation index of dextromethorphan | |
| US11357744B2 (en) | Bupropion as a modulator of drug activity | |
| US20230131854A1 (en) | Bupropion as a modulator of drug activity | |
| US20230099206A1 (en) | Bupropion as a modulator of drug activity | |
| US20220218698A1 (en) | Bupropion as a modulator of drug activity | |
| US20250205223A1 (en) | Bupropion as a modulator of drug activity | |
| US12109178B2 (en) | Bupropion as a modulator of drug activity | |
| US20230263750A1 (en) | Combination of dextromethorphan and bupropion for treating depression | |
| US20230233491A1 (en) | Combination of dextromethorphan and bupropion for treating depression | |
| US20210267967A1 (en) | Bupropion as a modulator of drug activity | |
| US20210023075A1 (en) | Bupropion as a modulator of drug activity | |
| CA3126062A1 (en) | Combination of dextromethorphan and bupropion for treating depression | |
| WO2021202419A1 (en) | Use of bupropion and dextromethorphan combinations for treating neurological disorders | |
| US20250090521A1 (en) | Bupropion as a modulator of drug activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250227 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250227 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250318 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250318 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250318 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250326 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250407 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250407 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250407 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250516 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251216 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260526 |